Clinical trial
A Randomized Placebo Controlled Study of OSI-774 (Erlotinib HCl, Tarceva[TM]) in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease
NCT00036647 is registered in ClinicalTrials.gov with OSI Pharmaceuticals as lead sponsor.
Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.
Registry record
As filed in ClinicalTrials.gov.
- Title
- A Randomized Placebo Controlled Study of OSI-774 (Erlotinib HCl, Tarceva[TM]) in Patients With Incurable Stage IIIB/IV Non-small Cell Lung Cancer Who Have Failed Standard Therapy for Advanced or Metastatic Disease
- Lead sponsor
- OSI Pharmaceuticals
- Phase
- Phase 3
- Overall status
- Completed
- Start date
- November 1, 2001
- Completion date
- January 30, 2004
- Enrollment
- 731 (actual)
- Sites
- 97
Conditions
As the registry lists them; a condition with its own page is linked.